Food and Drug Administration (FDA) approved a groundbreaking oral GLP-1 weight-loss medication the Wegovy pill from Novo Nordisk marking the first time a glucagon-like peptide-1 (GLP-1) receptor agonist for weight management can be taken as a daily tablet rather than by injection
Responses can vary based on individual factors such as genetics, metabolism, lifestyle, and overall health history
Achari further noted the lack of direct scientific evidence, since most trials have included patients with obesity and diabetes, not elite athletes
Type II diabetes, for example, becomes more manageable with a healthier lifestyle and weight loss, but is not curable
Contraindications: No known contraindications.
When multiple lines of evidence point in the same physiological direction, negative translational outcomes should be scrutinized for methodological rather than biological causes